CRANBURY, N.J., June 25, 2018 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a biopharmaceutical
company developing targeted, receptor-specific peptide therapeutics
for the treatment of diseases with significant unmet medical need
and commercial potential, today announced that it has been added to
the Russell 3000® Index as part of the annual Russell U.S. Index
reconstitution. The addition was effective as of the U.S.
market opening today.
Membership in the Russell 3000® Index remains in place for one
year, with automatic inclusion in the large-cap Russell 1000® or
small-cap Russell 2000® Index as well as the appropriate growth and
value style indexes. FTSE Russell determines membership for
its Russell indexes primarily by objective, market-capitalization
rankings and style attributes.
Russell indexes are widely used by investment managers and
institutional investors as the basis for index funds and as
benchmarks for active investment strategies. Approximately
$9 trillion in assets are benchmarked
against Russell's U.S. indexes. Russell indexes are part of
FTSE Russell, a leading global index provider.
For more information on the Russell 3000® Index and the Russell
US Indexes reconstitution, go to the "Russell Reconstitution"
section on the FTSE Russell website.
About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company
developing targeted, receptor-specific peptide therapeutics for the
treatment of diseases with significant unmet medical need and
commercial potential. Palatin's strategy is to develop products and
then form marketing collaborations with industry leaders in order
to maximize their commercial potential. For additional information
regarding Palatin, please visit Palatin's website at
www.Palatin.com.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin
Technologies, Inc., such as statements about potential actions by
regulatory agencies relating to its products in development and
market acceptance of its products in development, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and as that term is defined in the Private Securities
Litigation Reform Act of 1995. Palatin intends that such
forward-looking statements be subject to the safe harbors created
thereby. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that could cause Palatin's
actual results to be materially different from its historical
results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of nonclinical,
preclinical and toxicology studies, result of clinical trials,
regulatory actions by the FDA and other regulatory agencies and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating for events that
occur after the date of this press release.
View original content with
multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-added-to-russell-3000-index-300671888.html
SOURCE Palatin Technologies, Inc.